ResearcherOno Pharmaceutical Co., Ltd.No recent work listed
Project Leader
Known by name at one institution; no external author ID yet. Name as it appears in ClinicalTrials.gov.
Their work
Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.
- Pancreatic cancer papers
- 0
- Pancreatic cancer trials
- 3
- Pancreatic cancer grants
- 0
- Collaborators
- 0
2021: 2 trials · 2022: none · 2023: 1 trial
Trials 3
- A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in… Study director NCT06532331↗
- An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Pa… Study director NCT06532344↗
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (… Study director NCT06538207↗
Closest collaborators
No collaborators recorded.
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.